Portsmouth Business Crime Reduction Partnership

What Portsmouth Business Crime Reduction Partnership does

Ausun Pharmaceutical is a China-based, publicly listed specialty active pharmaceutical ingredient (API) manufacturer and CDMO provider founded in 2010 and listed on the Shanghai Stock Exchange (ticker 603229) in May 2017. The company develops and produces complex chiral-structured APIs across eight therapeutic categories — liver disease (Entecavir), respiratory, cardiovascular, high-end fluorine products, prostaglandins, antibacterial, gout (Febuxostat), and anti-tumor — supplying global pharmaceutical manufacturers and CDMO clients with products exported to Europe, the United States, Japan, and South Korea. Its technology platform is built around multi-chiral stereochemistry synthesis, high-difficulty process development, and GMP-compliant production supported by a thermal safety laboratory equipped with ARC, RC1, and DSC instruments for reaction risk assessment and SIL classification.

The company generates revenue through three primary streams: sale of proprietary specialty APIs, sale of pharmaceutical intermediates to global pharma companies, and CDMO/custom manufacturing services for clients requiring custom synthesis and scale-up. Pricing is not publicly disclosed; commercial engagement is conducted through direct B2B sales relationships supported by a sales team reachable via dedicated phone and email. Ausun differentiates itself by holding a comprehensive international regulatory certification portfolio — US FDA, EU GMP (with CEP), Japan PMDA, China NMPA, Russia GMP, plus ISO 14001 and ISO 45001 — and by operating the first academician workstation established within a Chinese chemical/pharmaceutical company, anchored by an R&D team of over 200 doctoral and master's degree holders and partnerships with the Chinese Academy of Medical Sciences, Zhejiang University, Zhengzhou University, the Shanghai Institute of Organic Chemistry, China Pharmaceutical University, and others. Annual R&D investment has exceeded 12% of revenue, reaching 15.51% in 2019.

The firm is pursuing a vertical integration strategy from intermediates to APIs to finished dosage forms ("pharmaceutical intermediates – APIs – preparations"一体化), and was the subject of a 2014 technology transfer of the Class 1 new drug BZP (for stroke) from Zhengzhou University. Headcount stands at approximately 800 employees. Financial momentum is positive, with H1 2020 revenue up 62.38% year-over-year and net profit up 69.46% year-over-year, coinciding with the 2020 receipt of Russian GMP certification that opens additional export markets.

Name

Portsmouth Business Crime Reduction Partnership

Legal name

浙江星空药业股份有限公司

Website

https://pbcrp.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Zhejiang Ausun Pharmaceutical is a publicly listed Chinese specialty API manufacturer and CDMO provider that develops complex chiral-structured active pharmaceutical ingredients across eight therapeutic categories for global pharmaceutical clients exported to the EU, US, Japan, and South Korea.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Contract manufacturing services
• Pharmaceutical intermediates
• GMP-compliant manufacturing
• Chiral synthesis APIs

Headquarters

HQ city

Portsmouth

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Active Pharmaceutical Ingredient (API) Sales: Research, development, production and sale of specialty active pharmaceutical ingredients across eight therapeutic categories: liver disease, respiratory, cardiovascular, high-end fluorine products, prostaglandins, antibacterial, gout, and anti-tumor.
2. Pharmaceutical Intermediates Sales: Production and sale of key pharmaceutical intermediates to global pharmaceutical companies.
3. CDMO / Custom Manufacturing: Custom processing and R&D services provided to pharmaceutical customers, including custom synthesis and process development per client specifications.
4. Contract Manufacturing: Commissioned manufacturing for large international pharmaceutical companies as part of the integration strategy toward 'pharmaceutical intermediates, APIs, preparations'一体化 upgrade.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

The company researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) across eight therapeutic categories (liver disease, respiratory, cardiovascular, high-end fluorine products, prostaglandins, antibacterial, gout, anti-tumor) including products such as Entecavir, Febuxostat, Posaconazole, Apixaban, Nebivolol, Macitentan, Sugammadex, and Tofacitinib Citrate. It also provides CDMO (Contract Development and Manufacturing Organization) services, performing custom synthesis and process development to convert R&D results into GMP-compliant industrial production for pharmaceutical clients.

Product overview

Ausun Pharmaceutical is a pharmaceutical manufacturer offering two main product/service lines: Active Pharmaceutical Ingredients (原料药) across eight therapeutic categories (liver disease, respiratory, cardiovascular, fluorine products, prostaglandins, antibacterial, gout, anti-tumor), and CDMO services for contract development and manufacturing. The company operates as an integrated pharmaceutical enterprise combining API production with custom manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (原料药) Active pharmaceutical ingredients (APIs) manufactured under GMP requirements for eight therapeutic categories: liver disease (e.g., Entecavir), respiratory, cardiovascular (e.g., Nebivolol, Apixaban), high-end fluorine products, prostaglandins (e.g., Macitentan), antibacterial, gout (e.g., Febuxostat), and anti-tumor (e.g., Posaconazole). Additional products include Iv fluconazole, Ramelteon, Sugammadex, and Tofacitinib Citrate. Designed for global pharmaceutical companies requiring DMF-registered APIs with complex chiral structures.
• CDMO (Contract Development and Manufacturing Organization) Services Contract development and manufacturing services providing custom processing and research services following GMP requirements. The service rapidly transforms R&D results into industrial production within specified timeframes to meet pharmaceutical client specifications.

Quantifiable outcome

• Over 12% annual R&D investment as share of revenue; 15.51% in 2019
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core.

• Chinese Academy of Medical Sciences (中国医学科学院)coreStrategic or Co-development PartnerAcademic partnership for joint research and development of pharmaceutical products. Part of the company's broader 'production, learning, and research' integration strategy to leverage external innovation capabilities.
• Zhengzhou University (郑州大学)coreStrategic or Co-development PartnerZhengzhou University signed a technology transfer agreement with the company in 2014 for BZP, a Class 1 new drug for stroke treatment. The partnership demonstrates the company's commitment to acquiring innovative drug development technologies.
• Zhejiang University (浙江大学)coreStrategic or Co-development PartnerAcademic partnership for joint research and development. Zhejiang University is listed among the university's recruitment targets in the campus recruitment program.
• Chinese Academy of Sciences Shanghai Institute of Organic Chemistry (中科院上海有机化学研究所)coreStrategic or Co-development PartnerCollaborative R&D partnership with the Shanghai Institute of Organic Chemistry for advanced organic synthesis and process development.
• Beijing University of Chemical Technology (北京化工大学)coreStrategic or Co-development PartnerAcademic partnership for R&D collaboration, leveraging the university's expertise in chemical engineering and process technology.
• Nankai University (南开大学)coreStrategic or Co-development PartnerAcademic partnership for joint research and development. Nankai University is listed among the university's recruitment targets.
• Zhejiang University of Technology (浙江工业大学)coreStrategic or Co-development PartnerAcademic partnership. Listed among university recruitment targets indicating ongoing talent pipeline and research collaboration.
• China Pharmaceutical University (中国药科大学)coreStrategic or Co-development PartnerAcademic partnership. China Pharmaceutical University is a premier pharmacy education institution in China and a key recruitment target for talent and research collaboration.
• Zhejiang University (浙江大学)coreStrategic or Co-development PartnerPremier Chinese university included in campus recruitment program and research partnerships. Collaboration covers joint product development and talent development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Novasep: European-headquartered CDMO offering custom synthesis and complex small-molecule API manufacturing. Competes for global pharma CDMO programs using similar chemistry capabilities and GMP quality systems.
• WuXi AppTec / WuXi STA (药明康德): China's largest end-to-end CRO/CDMO with global small-molecule and biologics manufacturing capacity. While much larger and more diversified, the WuXi STA subsidiary directly competes for the same CDMO and small-molecule API customers.
• Hetero Drugs / Cambrex (now part of Permira): Hetero is a large Indian specialty API manufacturer with strong FDA compliance and global generics footprint; Cambrex is a global small-molecule API CDMO. Both benchmark the competitive set in international specialty API / CDMO that Ausun targets.
• Lonza Small-Molecules API: Global leader in contract small-molecule API development and manufacturing with extensive GMP footprint. A benchmark for what fully-scaled specialty CDMOs can offer, and a competitor for premium Western innovator supply contracts.

Direct peers

• Zhejiang Huahai Pharmaceutical (华海药业): Large Chinese specialty API manufacturer with US FDA, EU GMP approvals and significant US generics exposure. Both companies target complex small-molecule APIs for global generic and innovator pharma, making the business models and customer overlap closely comparable.
• Zhejiang Hisoar Pharmaceutical (海正药业): Long-established Chinese API manufacturer with FDA-approved facilities and a broad internationally certified specialty API portfolio. Directly competes in the same therapeutic categories and serves the same global pharmaceutical customers.
• Asymchem Laboratories (凯莱英医药): China-headquartered CDMO specializing in small-molecule API development and GMP manufacturing with FDA-approved facilities serving global pharma. Direct competitor in custom synthesis and CDMO services for global innovator clients.
• Apeloa Pharmaceutical (普洛药业): Chinese API and intermediates manufacturer with a CDMO offering and global export footprint. Comparable scale, similar specialty-API focus, and overlapping therapeutic categories (e.g., cardiovascular, anti-infectives).
• Zhejiang Jingxin Pharmaceutical (京新药业): Chinese specialty API and finished-formulation manufacturer with cardiovascular and CNS focus. Comparable in scale, GMP footprint, and vertical integration trajectory toward finished dosage forms.
• Tianjin Tianyao Pharmaceutical (天药股份): Chinese API manufacturer with FDA and EU GMP approvals serving commodity and specialty small molecules. Closely comparable in regulatory profile, export mix, and B2B pharmaceutical customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

• Xx.com/Crimemanager
• LinkedInlinkedin.com/company/portsmouth-bcrp

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Portsmouth Business Crime Reduction Partnership